移民政策：Co-delivering tariquidar和thrugh long-circulation脂质体的使用
建议p-gp抑制剂使用较高的有效能力克服MDR给好的结果。tariquidar等抑制剂在本文。P-gp,然而,可以进一步被表达在一般组织如血脑屏障,胃肠道的性质、脾脏和肾脏(Patel et al ., 2011)。最大化P-gp抑制剂的疗效以及减少毒性系统,就必须考虑限制P-gp抑制剂暴露以及抗癌药物的正常组织。这进一步导致增加肿瘤细胞co-localization。
移民政策：Co-delivering tariquidar和thrugh long-circulation脂质体的使用
在这篇文章中,作者沉溺于调查P-gp抑制剂co-delivery和药物的细胞毒性性质,即紫杉醇的细胞内肿瘤对MDR(耐多药)通过使用长循环脂质体(Patel et al ., 2011)。这些脂质体以及tariquidar描述重要耐药变异re-sensitization紫杉醇耐药的方差。这可能与增强紫杉醇的细胞内积累相关肿瘤。
移民政策：Co-delivering tariquidar和thrugh long-circulation脂质体的使用
proposed that p-gp inhibitors with higher efficacious ability are to be used to show good results to overcome MDR. Such inhibitor is taken in the article as tariquidar. P-gp, however, can further be expressed within general tissues such as the barriers in the blood brain, track of gastrointestinal nature, spleen as well as kidney (Patel et al., 2011). For maximizing the P-gp inhibitor efficacy as well as reducing the toxicity systemically, it becomes essential to consider limiting the P-gp inhibitors exposure as well as the drugs of anti-cancer for normal tissues. This further results in increasing the tumor cells co-localization.
移民政策：Co-delivering tariquidar和thrugh long-circulation脂质体的使用
Within the article, the authors indulged in investigating the P-gp inhibitor co-delivery and drug of cytotoxic nature, namely paclitaxel within the cells of tumor for revering the MDR (multi-drug resistance) through the use of liposomes with long circulation (Patel et al., 2011). These liposomes along with tariquidar depicted essential resistant variant re-sensitization for the paclitaxel resistant variance. This could have a correlation with enhanced paclitaxel accumulation within the cells of tumor.
